Matt McElheron

Matt McElheron

Auto-generated profile, based on publicly available information

Matt McElheron

School of Medicine, Trinity College Dublin, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
HHHeike C. Hawerkamp
Heike C. Hawerkamp
ADAdam Dyer
Adam Dyer
NPNeha D. Patil
Neha D. Patil
MMMatt McElheron
Matt McElheron
NONiamh O’dOwd
Niamh O’dOwd
PFPadraic G. Fallon
Padraic G. Fallon
Clinical outcomes from infection with SARS-CoV-2, the cause of the COVID-19 pandemic, are remarkably variable ranging from asymptomatic infection to severe pneumonia and death. One of the key drivers of this variability is differing trajectories in the immune response to SARS-CoV-2 infection. Many studies have noted markedly elevated cytokine levels in severe COVID-19, although results vary by cohort, cytokine studied and sensitivity of assay used. We assessed the immune response in acute COVID-19 by measuring 20 inflammatory markers in 118 unvaccinated patients with acute COVID-19 (median age: 70, IQR: 58-79 years; 48.3% female) recruited during the first year of the pandemic and 44 SARS-CoV-2 naïve healthy controls. Acute COVID-19 was associated with marked elevations in nearly all pro-inflammatory markers, whilst eleven markers (namely IL-1β, IL-2, IL-6, IL-10, IL-18, IL-23, IL-33, TNF-α, IP-10, G-CSF and YKL-40) were associated with disease severity. We observed significant correlations between nearly all markers elevated in those infected with SARS-CoV-2 consistent with widespread immune dysregulation. Principal component analysis highlighted a pro-inflammatory cytokine signature (with strongest contributions from IL-1β, IL-2, IL-6, IL-10, IL-33, G-CSF, TNF-α and IP-10) which was independently associated with severe COVID-19 (aOR: 1.40, 1.11-1.76, p=0.005), invasive mechanical ventilation (aOR: 1.61, 1.19-2.20, p=0.001) and mortality (aOR 1.57, 1.06-2.32, p = 0.02). Our findings demonstrate elevated cytokines and widespread immune dysregulation in severe COVID-19, adding further evidence for the role of a pro-inflammatory cytokine signature in severe and critical COVID-19.

11 January 2022 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
ADAdam Dyer
Adam Dyer
CNClaire Noonan
Claire Noonan
MMMatt McElheron
Matt McElheron
IBIsabella Batten
Isabella Batten
CRConor Reddy
Conor Reddy
SKSean P Kennelly
Sean P Kennelly

8 July 2022 in Viruses
Verified
Journal Article
Open access
PDF file
LGLaura Garcia
Laura Garcia
TWTom Woudenberg
Tom Woudenberg
JRJason Rosado
Jason Rosado
ADAdam Dyer
Adam Dyer
FDFrançoise Donnadieu
Françoise Donnadieu
SPStephane Pelleau
Stephane Pelleau
Serological assays capable of measuring antibody responses induced by previous infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been critical tools in the response to the COVID-19 pandemic. In this study, we use bead-based multiplex assays to measure IgG and IgA antibodies and IgG avidity to five SARS-CoV-2 antigens (Spike (S), receptor-binding domain (RBD), Nucleocapsid (N), S subunit 2, and Membrane-Envelope fusion (ME)). These assays were performed in several cohorts of healthcare workers and nursing home residents, who were followed for up to eleven months after SARS-CoV-2 infection or up to six months after vaccination. Our results show distinct kinetic patterns of antibody quantity (IgG and IgA) and avidity. While IgG and IgA antibody levels waned over time, with IgA antibody levels waning more rapidly, avidity increased with time after infection or vaccination. These contrasting kinetic patterns allow for the estimation of time since previous SARS-CoV-2 infection. Including avidity measurements in addition to antibody levels in a classification algorithm for estimating time since infection led to a substantial improvement in accuracy, from 62% to 78%. The inclusion of antibody avidity in panels of serological assays can yield valuable information for improving serosurveillance during SARS-CoV-2 epidemics.

20 October 2026 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
SCSally Campbell
Sally Campbell
RORóisín O'REilly
Róisín O'REilly
OAOla Ahmed
Ola Ahmed
MMMatt McElheron
Matt McElheron
WCWilliam C. Chapman
William C. Chapman
COCliona O'FArrelly
Cliona O'FArrelly